To sum up, the mechanism of action by which FXF treats pulmonary fibrosis may be related to the regulation of several pathways, like IL-17, AGE-RAGE, TNF, HIF-1, PI3K-AKT, NOD-like receptor, T/B cell receptor, and virus infection-related pathways. Here, AKT1 is linked to viral infectious disease.